Literature DB >> 26057490

Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Alenka Trampuš Bakija1, Maruša Debeljak1, Irena Preložnik Zupan2, Majda Benedik Dolničar3, Jernej Kovač1, Janez Jazbec3.   

Abstract

BACKGROUND: Heterogeneous bleeding phenotypes are observed in haemophilia A patients with the same mutation in the F8 gene. Specific mutations in the A2 domain of factor VIII are associated with mild haemophilia and a higher risk of inhibitor development. Double mutations in mild haemophilia A are rarely reported. In this study, we investigated the in vitro function of factor VIII, performing different specific and global coagulation assays, observed clinical characteristics and assessed the possible predictive diagnostic value of the differences.
MATERIALS AND METHODS: The clinical features of haemophiliacs with a mild phenotype were reviewed. Blood samples were obtained and analysed for mutations and coagulation assays: activated partial thromboplastin time, one-stage and chromogenic factor VIII activity, factor VIII antigen and rotational thromboelastometry.
RESULTS: We report on a cohort of 22 patients with double Glu113Asp, Arg593Cys mutations. All our patients have a quantitative defect of factor VIII and preserved similar functional activity. Factor VIII activities measured by the one-stage or chromogenic method were not discrepant, although the chromogenic assay resulted in 20% lower factor VIII activities. Waveform analysis showed a lower maximum value of the second derivative curve (Max2) of APTT with curve shape alternation, while thromboelastometry (INTEM) showed low sensitivity in comparison to results in a normal population. DISCUSSION: In genotyping, the coexistence of a second mutation should never be excluded, especially in cases of discordant clinical presentation. Waveform analysis correlates better with factor VIII activity than thromboelastometry and the Max2 parameter could provide additional information in managing haemophilia patients. The utility of specific factor activity and global haemostatic assays in general practice still needs to be investigated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26057490      PMCID: PMC4624539          DOI: 10.2450/2015.0321-14

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  43 in total

1.  Multi-centre investigation on reference ranges for ROTEM thromboelastometry.

Authors:  Thomas Lang; Anne Bauters; Siegmund L Braun; Bernd Pötzsch; Klaus-Werner von Pape; Hans-Jürgen Kolde; Meret Lakner
Journal:  Blood Coagul Fibrinolysis       Date:  2005-06       Impact factor: 1.276

2.  Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH.

Authors:  M Chitlur; G E Rivard; D Lillicrap; K Mann; M Shima; G Young
Journal:  J Thromb Haemost       Date:  2014-01       Impact factor: 5.824

3.  Spectrum of F8 gene mutations in haemophilia A patients from Slovenia.

Authors:  M Debeljak; L Kitanovski; A Trampuš Bakija; M Benedik Dolničar
Journal:  Haemophilia       Date:  2012-09-07       Impact factor: 4.287

4.  Risk of inhibitor development in mild haemophilia A increases with age.

Authors:  E P Mauser-Bunschoten; I E M Den Uijl; R E G Schutgens; G Roosendaal; K Fischer
Journal:  Haemophilia       Date:  2011-08-19       Impact factor: 4.287

Review 5.  Genetic risk factors for inhibitors to factors VIII and IX.

Authors:  J Oldenburg; A Pavlova
Journal:  Haemophilia       Date:  2006-12       Impact factor: 4.287

Review 6.  The protein structure and effect of factor VIII.

Authors:  Hong Fang; Lemin Wang; Hongbao Wang
Journal:  Thromb Res       Date:  2006-02-17       Impact factor: 3.944

Review 7.  Factor VIII inhibitors in mild and moderate-severity haemophilia A.

Authors:  C R Hay
Journal:  Haemophilia       Date:  1998-07       Impact factor: 4.287

8.  Biphasic activated partial thromboplastin time waveform and adverse events in non-intensive care unit patients.

Authors:  Eve Y Smith; Linda A Charles; Elizabeth M Van Cott
Journal:  Am J Clin Pathol       Date:  2004-01       Impact factor: 2.493

Review 9.  Diagnosis of factor VIII deficiency.

Authors:  B Verbruggen; P Meijer; I Novákova; W Van Heerde
Journal:  Haemophilia       Date:  2008-07       Impact factor: 4.287

10.  Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation.

Authors:  Cheng Hock Toh; Lawrence O Ticknor; Colin Downey; Alan R Giles; Ray C Paton; Richard Wenstone
Journal:  Intensive Care Med       Date:  2002-11-22       Impact factor: 17.440

View more
  3 in total

1.  An Evaluation of the Activated Partial Thromboplastin Time Waveform.

Authors:  Takeshi Matsumoto; Hideo Wada; Naoki Fujimoto; Junki Toyoda; Yasunori Abe; Kohshi Ohishi; Yoshiki Yamashita; Makoto Ikejiri; Kei Hasegawa; Kei Suzuki; Hiroshi Imai; Kaname Nakatani; Naoyuki Katayama
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-08       Impact factor: 2.389

2.  Production of Wilson Disease Model Rabbits with Homology-Directed Precision Point Mutations in the ATP7B Gene Using the CRISPR/Cas9 System.

Authors:  Weihua Jiang; Lili Liu; Qiurong Chang; Fengying Xing; Zhengwen Ma; Zhenfu Fang; Jing Zhou; Li Fu; Huiyang Wang; Xingxu Huang; Xuejin Chen; Yao Li; Shangang Li
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

3.  Burden of mild haemophilia A: Systematic literature review.

Authors:  Flora Peyvandi; Fatemeh Tavakkoli; Diana Frame; Jennifer Quinn; Benjamin Kim; Adebayo Lawal; Mimi C Lee; Wing Y Wong
Journal:  Haemophilia       Date:  2019-07-11       Impact factor: 4.287

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.